Compare EEFT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEFT | LQDA |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | 1996 | 2020 |
| Metric | EEFT | LQDA |
|---|---|---|
| Price | $73.62 | $40.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $94.00 | $41.00 |
| AVG Volume (30 Days) | 538.7K | ★ 952.0K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.05 | ★ 51.81 |
| EPS | ★ 6.84 | N/A |
| Revenue | ★ $4,244,200,000.00 | $158,320,000.00 |
| Revenue This Year | $8.27 | $278.87 |
| Revenue Next Year | $6.03 | $57.13 |
| P/E Ratio | $10.41 | ★ N/A |
| Revenue Growth | 6.38 | ★ 1031.18 |
| 52 Week Low | $63.73 | $11.85 |
| 52 Week High | $114.25 | $46.67 |
| Indicator | EEFT | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 63.40 | 61.28 |
| Support Level | $72.35 | $31.75 |
| Resistance Level | $75.93 | $46.67 |
| Average True Range (ATR) | 2.45 | 1.84 |
| MACD | 0.89 | 0.29 |
| Stochastic Oscillator | 98.62 | 89.80 |
Euronet Worldwide Inc is a provider of electronic financial transaction solutions. It offers payment and transaction processing and distribution solutions to financial institutions, retailers, service providers, and individual consumers. The company's product offerings include comprehensive ATM, POS, card outsourcing, card issuing and merchant acquiring services, software solutions, money transfer services, etc. Its reportable operating segments are EFT Processing, epay, and Money Transfer. Maximum revenue is derived from its Money Transfer segment, which provides money transfer services across the world under the brand names Ria, AFEX, IME, and xe. Geographically, the company generates maximum revenue from the United States, followed by Germany, India, France, Greece, and other regions.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.